5-<4-<(tert-Butyldimethylsilyl)oxy>-2,3,5-trimethylphenoxy>-2,2-dimethylpentanoic acid | 112109-67-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 5-<4-<(tert-Butyldimethylsilyl)oxy>-2,3,5-trimethylphenoxy>-2,2-dimethylpentanoic acid
• 英文别名: 5-{4-[(tert-Butyldimethylsilyl)oxy]-2,3,5-trimethylphenoxy}-2,2-dimethylpentanoic acid；5-[4-[Tert-butyl(dimethyl)silyl]oxy-2,3,5-trimethylphenoxy]-2,2-dimethylpentanoic acid；5-[4-[tert-butyl(dimethyl)silyl]oxy-2,3,5-trimethylphenoxy]-2,2-dimethylpentanoic acid
• CAS: 112109-67-8
• 化学式: C₂₂H₃₈O₄Si
• 分子量: 394.627
• InChiKey: SXSNPBNNHOXAGT-UHFFFAOYSA-N

物化性质

• 沸点：
  493.8±45.0 °C(predicted)
• 密度：
  0.990±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.27
• 重原子数：
  27
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-<4-<(tert-Butyldimethylsilyl)oxy>-2,3,5-trimethylphenoxy>-2,2-dimethylpentanoic acid 在 四丁基氟化铵 、 溶剂黄146 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 以83%的产率得到5-(4-Hydroxy-2,3,5-trimethylphenoxy)-2,2-dimethylpentanoic acid
  参考文献：
  名称：

  Studies on hindered phenols and analogs. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation

  摘要：

  A series of hindered phenols were investigated as hypolipidemic and/or hypoglycemic agents with ability to inhibit lipid peroxidation. 1,3-Benzoxathioles (9 and 22), phenoxypentanoic acid (34), phenoxypentanol (35a), phenoxynonanol (35b), phenylchloropropionic acid having a chromanyl group (25), and a thiazolidine compound (27) derived from 25, all having a hindered phenol group, were prepared and examined. Compound 27 showed the expected biological properties in vivo and in vitro without any liver weight increase. Biological activities of the analogous thiazolidine compounds, 43-58, were compared. Thus, (+/-)-5-[4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]- benzyl]-2,4-thiazolidinedione (27) (CS-045) was found to have all of our expected properties and was selected as a candidate for further development as a hypoglycemic and hypolipidemic agent.

  DOI：

  10.1021/jm00122a022
• 作为产物：
  描述：

  4-((t-butyldimethylsilyl)oxy)-2,3,5-trimethylphenol 在 sodium hydroxide 、 正丁基锂 、 四丁基硫酸氢铵 、 sodium hydride 、 sodium carbonate 、 二异丙胺 作用下， 以 水 为溶剂， 反应 3.75h， 生成 5-<4-<(tert-Butyldimethylsilyl)oxy>-2,3,5-trimethylphenoxy>-2,2-dimethylpentanoic acid
  参考文献：
  名称：

  Studies on hindered phenols and analogs. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation

  摘要：

  A series of hindered phenols were investigated as hypolipidemic and/or hypoglycemic agents with ability to inhibit lipid peroxidation. 1,3-Benzoxathioles (9 and 22), phenoxypentanoic acid (34), phenoxypentanol (35a), phenoxynonanol (35b), phenylchloropropionic acid having a chromanyl group (25), and a thiazolidine compound (27) derived from 25, all having a hindered phenol group, were prepared and examined. Compound 27 showed the expected biological properties in vivo and in vitro without any liver weight increase. Biological activities of the analogous thiazolidine compounds, 43-58, were compared. Thus, (+/-)-5-[4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]- benzyl]-2,4-thiazolidinedione (27) (CS-045) was found to have all of our expected properties and was selected as a candidate for further development as a hypoglycemic and hypolipidemic agent.

  DOI：

  10.1021/jm00122a022

文献信息

• Studies on hindered phenols and analogs. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation
  作者：Takao Yoshioka、Takashi Fujita、Tsutomu Kanai、Yuichi Aizawa、Tomoyuki Kurumada、Kazuo Hasegawa、Hiroyoshi Horikoshi

  DOI：10.1021/jm00122a022

  日期：1989.2

  A series of hindered phenols were investigated as hypolipidemic and/or hypoglycemic agents with ability to inhibit lipid peroxidation. 1,3-Benzoxathioles (9 and 22), phenoxypentanoic acid (34), phenoxypentanol (35a), phenoxynonanol (35b), phenylchloropropionic acid having a chromanyl group (25), and a thiazolidine compound (27) derived from 25, all having a hindered phenol group, were prepared and examined. Compound 27 showed the expected biological properties in vivo and in vitro without any liver weight increase. Biological activities of the analogous thiazolidine compounds, 43-58, were compared. Thus, (+/-)-5-[4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]- benzyl]-2,4-thiazolidinedione (27) (CS-045) was found to have all of our expected properties and was selected as a candidate for further development as a hypoglycemic and hypolipidemic agent.